Descartes-25 in Relapsed/Refractory Multiple Myeloma

• Status: Not yet recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cartesian Therapeutics

Criteria

Inclusion Criteria:

• 18 years and older'

• diagnosed with active R/RMM, who have failed 2 lines of treatment

• have measurable disease

Exclusion Criteria:

• Patients with active plasma cell leukemia